Home Tools
Log in
Cart

Inhibitory Antibodies

A monoclonal antibody is secreted by a single B lymphocyte clone which can only produce a kind of proprietary antibody against an antigen-determining cluster, and has the characteristics of single biological activity and particular specificity of binding with antigen.

The active sites of monoclonal antibody drugs involve a variety of tumor-related signaling pathways and targets. For example, the most common targets are epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF), and epidermal growth factor receptor -2 (her-2 /neu, or egfr-2). Besides, there is a group of targets that are getting a lot of attention called “immune checkpoints”.

After the activation of immune cells that regulate the anti-tumor immune response, a variety of highly expressed receptors on the surface of immune cells bind to the highly expressed ligands on the surface of tumor cells to reduce the strength of the immune response, thus down-regulating the intensity of tumor-related immune response. These immunoregulatory sites are known as immune checkpoints. Currently, the most widely studied immune checkpoints are PD-1, PD-L1, and CTLA-4.

Targetmol provides 30 monoclonal antibody drugs, including the above immune checkpoint inhibitors and other types of targeted antibody inhibitors, for scientific research only.

Cat. No. Product name CAS No. Purity Chemical Structure
T36653 Anti-SARS-80R mAb 98%
Anti-SARS-80R mAb (SARS-80R) is a human IgG1 monoclonal antibody that is derived from CHO cells. Its main function is to selectively bind to the Spike (S1) prote...
T36654 Anti-SARS-CoV-2 Spike mAb (CR3022) 98%
Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody derived from CHO cells. It specifically targets the S1 domain of the Spike protein in both...
T35394 Sintilimab (anti-PD-1) 2072873-06-2 98%
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding ...
T9914 Vedolizumab 943609-66-3 98%
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis.
T35397 Sacituzumab (anti-Trop-2) 1796566-95-4 98%
The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomera...
T11126 Durvalumab 1428935-60-7 98%
Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 n...
T9923 Nimotuzumab 828933-51-3 98%
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
T36651 Anti-MERS-2E6 mAb 98%
Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody, is expressed in CHO cells. It effectively competes with the virus Spike protein for binding to ...
T9904 Bevacizumab 216974-75-3 98%
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibito...
T38951 Isatuximab 1461640-62-9 98%
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu...
T36655 Anti-Spike-RBD mAb 98%
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach f...
T9922 Matuzumab 339186-68-4 98%
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ...
T35389 Sarilumab (anti-IL-6Rα) 98%
T36656 Anti-Spike-RBD Single Domain mAb 98%
The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the...
T12706 Reslizumab 241473-69-8 98%
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
T39057 Rozanolixizumab 1584645-37-3 98%
Rozanolixizumab (UCB7665) is a humanized monoclonal antibody (IgG4P) that exhibits high affinity for the human neonatal Fc receptor (FcRn). Its application lies ...
T9931 Meplazumab 2413715-21-4 98%
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
T36652 Anti-MERS-3A1 mAb 98%
Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-C...
T35396 Spartalizumab (anti-PD-1) 98%
T9917 Denosumab 615258-40-7 98%
Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
Anti-SARS-80R mAb
T36653
Anti-SARS-80R mAb (SARS-80R) is a human IgG1 monoclonal antibody that is derived from CHO cells. Its main function is to selectively bind to the Spike (S1) prote...
Anti-SARS-CoV-2 Spike mAb (CR3022)
T36654
Anti-SARS-CoV-2 Spike mAb (CR3022) is a human monoclonal IgG1 antibody derived from CHO cells. It specifically targets the S1 domain of the Spike protein in both...
Sintilimab (anti-PD-1)
T35394
Sintilimab (IBI308) is a humanized IgG4 monoclonal antibody with significant anti-tumor activity that restores endogenous anti-tumor T-cell responses by binding ...
Vedolizumab
T9914
Vedolizumab is a humanized monoclonal antibody that targets the α4β7 integrin for the treatment of Crohn's disease and ulcerative colitis.
Sacituzumab (anti-Trop-2)
T35397
The antibody moiety of sacituzumab govitecan selectively binds to TROP2. After internalization and proteolytic cleavage, SN-38 selectively stabilizes topoisomera...
Durvalumab
T11126
Durvalumab is an anti-PD-L1 monoclonal antibody, humanized.Durvalumab completely blocked the binding of PD-L1 to PD-1 and CD80, and the IC50s were 0.1 and 0.04 n...
Nimotuzumab
T9923
Nimotuzumab is a humanized therapeutic monoclonal antibody against epidermal growth factor receptor EGFR).
Anti-MERS-2E6 mAb
T36651
Anti-MERS-2E6 mAb (MERS-2E6), a human IgG1 neutralizing antibody, is expressed in CHO cells. It effectively competes with the virus Spike protein for binding to ...
Bevacizumab
T9904
Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibito...
Isatuximab
T38951
Isatuximab is a monoclonal antibody targeting the transmembrane receptor and ectoenzyme CD38 , a protein highly expressed on hematological malignant cells, inclu...
Anti-Spike-RBD mAb
T36655
Anti-Spike-RBD mAb is a CHO cell derived human monoclonal IgG1 antibody. Blocking the interaction of spike protein and ACE2 is a potential therapeutic approach f...
Matuzumab
T9922
Matuzumab is a humanized monoclonal antibody used in cancer treatment. It has a high affinity for EGFR frequently associated with the growth of blood vessels in ...
Sarilumab (anti-IL-6Rα)
T35389
Anti-Spike-RBD Single Domain mAb
T36656
The Anti-Spike-RBD Single Domain mAb is a monoclonal antibody derived from CHO cells in Alpaca. It is composed of VHH-huFc and exhibits a strong affinity for the...
Reslizumab
T12706
Reslizumab is humanized monoclonal antibodies that target interleukin-5 (IL-5) for the treatment of eosinophilic asthma.
Rozanolixizumab
T39057
Rozanolixizumab (UCB7665) is a humanized monoclonal antibody (IgG4P) that exhibits high affinity for the human neonatal Fc receptor (FcRn). Its application lies ...
meplazumab
T9931
meplazumab is a humanized anti-CD147 antibody, as add-on therapy in patients with COVID-19 pneumonia.
Anti-MERS-3A1 mAb
T36652
Anti-MERS-3A1 mAb (MERS-3A1) is a high-affinity human monoclonal IgG1 antibody derived from CHO cells. It effectively inhibits the interaction between the MERS-C...
Spartalizumab (anti-PD-1)
T35396
Denosumab
T9917
Denosumab is a monoclonal antibody given subcutaneously that inhibits osteoclast activity by targeting the RANK ligand
1 2 3